CLINICAL PROTOCOL & DATA MANAGEMENT ABSTRACT The Moores Cancer Center (MCC) Clinical Trials Office (CTO) provides a centralized resource for the conduct of cancer-related clinical research at University of California San Diego (UCSD) including the affiliated Rady Children?s Hospital. The purpose of the CTO is to provide an effective and efficient infrastructure to support MCC investigators in developing, implementing, and reporting on all cancer clinical research studies at MCC. The Moores Cancer Center Clinical Trials Office provides the following services: Serves as a central clinical research information repository that facilitates Center-wide communications, subject accrual tracking, and monitoring of the progression for all clinical studies from inception to final publication. Assists MCC investigators in the timely activation and administration of clinical studies, including the preparations and communications required for scientific, ethical, financial, and operational reviews as well as ongoing support for annual regulatory reviews. Assists clinicians in screening and enrolling patients for clinical research studies. Coordinates and ensures the completion of patient-specific study requirements. Provides data management support for clinical research studies. Prepares medical and research records for internal and external quality and compliance audits. Provides clinical research training and education to CTO staff and investigators related to best practices in conducting clinical research. Performs quality assurance activities and monitors compliance with federal requirements such as study registration to clinicaltrials.gov and NCI?s Clinical Trials Reporting Program. Communicates the availability of clinical studies to MCC physicians, referring physicians, and the public.
| Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888 |
| Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306 |
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
Showing the most recent 10 out of 862 publications
